Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 2—February 2002
Research

An Outbreak of Rift Valley Fever in Northeastern Kenya, 1997-98

Christopher W. Woods*Comments to Author , Adam M. Karpati*, Thomas Grein†, Noel McCarthy†, Peter Gaturuku§, Eric Muchiri§, Lee Dunster¶, Alden Henderson*, Ali S. Khan*, Robert Swanepoel#, Isabelle Bonmarin, Louise Martin**, Philip Mann††, Bonnie L. Smoak‡‡, Michael Ryan**, Thomas G. Ksiazek*, Ray R. Arthur**, Andre Ndikuyeze**, Naphtali N. Agata**, Clarence J Peters*, and the World Health Organization Hemorrhagic Fever Task Force
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †European Program for Intervention Epidemiology Training (EPIET), European Union, Saint-Maurice, France; EPICENTRE, Paris, France; §Kenya Ministry of Health, Nairobi, Kenya; ¶Kenyan Medical Research Institute, Nairobi, Kenya; #National Institutes of Virology (NIV), Sandringham, South Africa; **World Health Organization, African Regional Office, Harare, Zimbabwe; ††Médècins Sans Frontieres, Paris, France; ‡‡United States Army Medical Research Unit, Kenya; §§International Federation of the Red Cross and Red Crescent, Geneva, Switzerland; ¶¶Médècins du Monde, Paris, France; ##Africa Medical Research Foundation, Nairobi, Kenya

Main Article

Table 2

Demographic characteristics of persons enrolled in Rift Valley fever cross-sectional survey, Garissa District, Kenya, 1997-98

CharacteristicTotal (%)
n = 202Priora infection
(% of total)
 n=31Susceptibleb
n=171Acutec infection
(% of susceptible)
n=31
Age group (years)
<1540 (20)2 (5)382 (5)
15 to 65150 (74)25 (17)12528 (22)
>6512 (6)4 (33)81 (13)
Sex
Male103 (51)16 (16)8718 (21)
Female99 (49)15 (15)8413 (15)
Rural habitation161 (80)25 (16)13630 (22)
Household >4 persons74 (37)10 (14)6421 (33)

aAnti-RVF IgG antibody-positive (no immunoglobulin M [IgM]).

bTotal screened minus those with prior infection.

cAnti-Rift Valley fever virus IgM antibody-positive.

Main Article

1 Members of the World Health Organization (WHO) Hemorrhagic Fever Task Force, in addition to the listed authors, included Paul Arguin, David Ashford, Julianna Grant, Stuart Nichol, and Brian Plikaytis, Centers for Disease Control and Prevention; Marta Valenciano, European Program for Intervention Epidemiology Training, European Union; James N. Mwanzia, Philip Kangethe, Stephen A. Mileso, and Quinto Maloba, Kenya Ministry of Health; Manuela Dunster, Kenyan Medical Research Institute; Alan Kemp and Koos Coetzer, National Institutes of Virology, Sandringham, South Africa; Jean-Jacques Muyembe, Philip M. Mothoka, Gregory C. Gottlieb, John H. Bierke, and Glyn Davies, WHO, Geneva and African Regional Office; Saade Abdallah, International Federation of the Red Cross and Red Crescent; Elizabeth Nicore and Olivier West, Médècins du Monde; and Christine Grace Adhiambo, Africa Medical Research Foundation.

Page created: August 01, 2012
Page updated: August 01, 2012
Page reviewed: August 01, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external